IBDASE

Mucosal protease and their inhibitors in inflammatory bowel disease: From etiopathogenetic insight to innovative therapy

 Coordinatore UNIVERSITAET BERN 

 Organization address address: Hochschulstrasse 4
city: BERN
postcode: 3012

contact info
Titolo: Dr.
Nome: Daniel
Cognome: Lottaz
Email: send email
Telefono: +41 31 632 1278
Fax: +41 31 632 0585

 Nazionalità Coordinatore Switzerland [CH]
 Sito del progetto http://www.ibdase.org/
 Totale costo 4˙120˙034 €
 EC contributo 2˙973˙550 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-03-01   -   2011-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITAET BERN

 Organization address address: Hochschulstrasse 4
city: BERN
postcode: 3012

contact info
Titolo: Dr.
Nome: Daniel
Cognome: Lottaz
Email: send email
Telefono: +41 31 632 1278
Fax: +41 31 632 0585

CH (BERN) coordinator 0.00
2    GOETEBORGS UNIVERSITET

 Organization address address: VASAPARKEN
city: GOETEBORG
postcode: 405 30

contact info
Titolo: Prof.
Nome: Margareta
Cognome: Ahlqwist
Email: send email
Telefono: +46 31 786 3488
Fax: +46 31 786 4355

SE (GOETEBORG) participant 0.00
3    ISTITUTO EUROPEO DI ONCOLOGIA SRL

 Organization address address: Via Filodrammatici 10
city: MILANO
postcode: 20121

contact info
Titolo: Ms.
Nome: Ilaria
Cognome: Foti
Email: send email
Telefono: +39 0 257489295
Fax: +39 02 94375991

IT (MILANO) participant 0.00
4    JOHANNES GUTENBERG UNIVERSITAET MAINZ

 Organization address address: SAARSTRASSE 21
city: MAINZ
postcode: 55099

contact info
Titolo: Dr.
Nome: Karl Peter Christian
Cognome: Spath
Email: send email
Telefono: +49 6131 3925891
Fax: +49 6131 3924741

DE (MAINZ) participant 0.00
5    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Ms.
Nome: Marion
Cognome: Wolpers
Email: send email
Telefono: +32 16 326520
Fax: +32 16 326515

BE (LEUVEN) participant 0.00
6    PROGENIKA BIOPHARMA SA

 Organization address address: "Parque Tecnologico de Zamudio, Edificio 801 -A-, Planta 2"
city: DERIO - VIZCAYA
postcode: 48160

contact info
Titolo: Dr.
Nome: Gorka
Cognome: Ramirez
Email: send email
Telefono: +34 944064525

ES (DERIO - VIZCAYA) participant 0.00
7    SCIPROM SARL

 Organization address address: RUE DU CENTRE 70
city: Saint-Sulpice
postcode: 1025

contact info
Titolo: Dr.
Nome: Kirsten
Cognome: Leufgen
Email: send email
Telefono: +41 21 69302 61

CH (Saint-Sulpice) participant 0.00
8    UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA

 Organization address address: VIA ORAZIO RAIMONDO 18
city: ROMA
postcode: 173

contact info
Titolo: Prof.
Nome: Francesco
Cognome: Pallone
Email: send email
Telefono: +39 0672596376
Fax: +39 0672596391

IT (ROMA) participant 0.00
9    UNIVERSITE D'AUVERGNE CLERMONT-FERRAND 1

 Organization address address: Boulevard Francois Mitterand 49
city: Clermont-Ferrand
postcode: 63001

contact info
Titolo: Dr.
Nome: Laurent
Cognome: Claret
Email: send email
Telefono: +33 04 73 17 83 76
Fax: +33 4 73 17 83 71

FR (Clermont-Ferrand) participant 0.00
10    UNIVERSITY OF SOUTHAMPTON

 Organization address address: Highfield
city: SOUTHAMPTON
postcode: SO17 1BJ

contact info
Titolo: Ms.
Nome: Rachel
Cognome: Green
Email: send email
Telefono: +44 23 8079 5081
Fax: +44 23 8079 5025

UK (SOUTHAMPTON) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

gut    ibdase    pi    related    inflammatory    ibd    disease    mucosa    pis    expression       efficacy    human    models    microflora    clinical    intestinal    mucosal    patient   

 Obiettivo del progetto (Objective)

'IBDase addresses the etiology and pathogenesis of inflammatory bowel disease (IBD) with a multidisciplinary plan for innovative diagnosis and therapy focused on mucosal proteases and their inhibitors (P/PIs). The incidence of IBD, a multifactorial disease influenced by environmental factors in a background of complex genetic susceptibility, is rising, particularly among European children. Current therapies lack efficacy and specificity. The gut microflora plays a crucial role in IBD but the cause for this is still poorly understood. Research implicating P/PIs in gut mucosal inflammation requires further mechanistic insight and the P/PIs relevant in human IBD need to be identified. To this end we will identify human mucosal P/PI polymorphisms affecting expression levels and/or activity of P/PIs and analyse their genotype/phenotype associations in IBD patient cohorts across Europe. IBD-associated P/PIs will be characterised by biochemical properties, expression in human clinical samples and manipulation of experimental models. Their interaction with microflora will be examined in animal models with controlled colonisation of the gut and in vitro co-culture models of intestinal mucosa and bacteria. In vivo studies will use targeted, well-established and new mouse models and evaluate zebrafish as an IBD model. Molecular mechanisms for involvement of IBD specific P/PI gene variants in the inflammatory response will be proposed. Therapeutics development will focus on specific inhibition or promotion of proteolysis in the intestinal mucosa, and select at least three validated P/PI of the intestinal mucosa for follow-up in clinical trials. Embracing the concept of tailoring treatment to individual patient characteristics to increase efficacy and reduce side-effects, IBDase strengthens international visibility of IBD related research, policies and industry and fosters IBD related research to the benefit of European society in both patient care and economic interest.'

Altri progetti dello stesso programma (FP7-HEALTH)

BLUEPRINT (2011)

A BLUEPRINT of Haematopoietic Epigenomes

Read More  

EPI-MIGRANT (2011)

Identification of epigenetic markers underlying increased risk of T2D in South Asians

Read More  

FLUCURE (2010)

Development of novel antiviral drugs against Influenza

Read More